Arthritis, Rheumatoid
Conditions
Brief summary
To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.
Interventions
None listed
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least one claim for methotrexate during the variable-length pre-index period. * At least one claim for tofacitinib or bDMARDs between 01 February 2016 and 31 July 2019 (the identification period).
Exclusion criteria
* Patients with claims for other conditions for which bDMARDs are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study. * Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with (other) bDMARDs during the one-year pre-index period. * Patients with more than 1 bDMARD or bDMARD with tofacitinib filled on the index date will be removed from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Within 90 days after index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | In this outcome measure number of participants who were on combination therapy with index medication and who were on monotherapy during 12 months pre-index date were reported. Participants with a use of at least 1 of 4 specific csDMARDs (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide) within 90 days on or after the index date were considered as being treated with combination therapy. Participants who did not take any csDMARDs along with index medication were considered being treated with monotherapy. |
| Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Number of participants with most commonly used medications use during 12 months post index period are reported. The 25 most medications: 1) methotrexate sodium, 2) prednisone, 3) folic acid, 4) adalimumab, 5) etanercept, 6) acetaminophen/hydrocodone bitartrate, 7) hydroxychloroquine sulfate, 8) azithromycin, 9) levothyroxine sodium, 10) tramadol hydrochloride, 11) methylprednisolone, 12) gabapentin, 13) albuterol sulfate, 14) amoxicillin/clavulanate potassium, 15) omeprazole, 16) amoxicillin, 17) meloxicam, 18) tofacitinib citrate, 19) fluticasone propionate, 20) cyclobenzaprine hydrochloride, 21) diclofenac sodium, 22) duloxetine hydrochloride, 23) atorvastatin calcium, 24) leflunomide, 25) fluconazole. A participant could have received \>=1 most common medication. |
| Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Number of participants who used at least 1 opioid and NSAID during post-index period are reported. |
| Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | The mean number of pharmacy claims for opioids and NSAIDs during the post-index period are reported. A pharmacy claim was defined as a claim made by participants to their insurance provider in purchasing opioids and NSAIDs from the pharmacy. |
| Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Mean number of days from the index date to the first opioid and NSAIDs claim during post index period are reported. |
| Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Number of participants who used opioids and NSAIDs during tofacitinib persistency and post-persistency are reported. Persistence with the index medication was defined as not having a gap in therapy of at least 60 days between fills/infusions. |
| Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | The number of participants who used at least 1 oral corticosteroid during the 12 months post-index period are reported. |
| Number of Participants Who Were Non-persistent to Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Non-persistence was defined as the gap of at least 60 days in treatment with the index medication or switching to other biologic. |
| Number of Participants Who Switched Immediately From Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants were classified as switched immediately if they initiated a non-index bDMARD before a 60-day gap in index medication treatment. |
| Number of Participants Who Discontinued Then Restarted Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants were classified as discontinued and then restarted index medication if there was a gap in the index therapy of at least 60 days and the first medication observed after the gap was the index medication. |
| Number of Participants Who Discontinued Then Switched From Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants were classified as discontinued and then switched from index medication if there was a gap in the index therapy of at least 60 days and the first medication observed after the gap was a bDMARD (including tofacitinib) different from index medication. |
| Number of Participants Who Discontinued Without Switching or Restarting Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants were classified as discontinued without switching or restarting index medication if they had a gap in therapy of at least 60 days and there were no claims for either the index medication or a different bDMARD for the remainder of the follow-up period. |
| Number of Participants Who Switched Any Time From Index Medication | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Number of participants who switched from index medication to a biologic at any time during post-index period are reported. |
| Number of Participants Who Re-started Index Medication at Any Time | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants who had a claim for the index medication any time after they were considered non-persistent with the index treatment (i.e, including after switching) during the 12-month follow-up are reported. Non-persistence was defined as the gap of at least 60 days in treatment with the index medication or switching to other biologic. |
| Mean Medication Possession Ratio (MPR) for Methotrexate | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | MPR was calculated as the total days supply of methotrexate between the first and including the last prescription/administration divided by the time between the first through and including last biologic prescription/administration days supply. |
| Proportion of Days Covered (PDC) | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | The PDC was calculated based on total days supply over the 12 months follow-up. The PDC was calculated by using the date of service and the day supply for each fill of the index medication. |
| Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Participants with monotherapy who used additional csDMARD during post index period are reported. |
| Adherence to Cs-DMARDs in Participants With Combination Therapy | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Adherence was calculated as the total day supply for csDMARDs divided by the number of days from the first claim during the follow-up until the end of the follow-up. |
| All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause inpatient visits costs, outpatient visits costs and emergency room visits costs during 12 months post index period are reported. Inpatient visit costs consisted of expenses during hospital visit for formal admission. Outpatient visit costs consisted of expenses when participants visited hospital but not for formal admission. Emergency room visit costs consisted of expenses during visit to hospital emergency room. |
| Number of Participants Who Met Different Medication Effectiveness Criteria | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | Adherence criteria: PDC \>=0.8, proportion of days of supply during post-index period of 12 months.Dose escalation criteria: no increase in dose for index drug compared to starting dose during post-index period. Switch criteria: no switching from index drug to (different) biologic agent during post-index period. DMARD criteria: no addition of new csDMARD to index drug during post-index period. Oral glucocorticoid criteria: Participants with no claims for oral glucocorticoids in 6 months pre-index cannot receive oral glucocorticoids for greater than (\>)30 days between (index date +91 days) to (index date + 365 days); or participants with claims for oral glucocorticoids in 6 months pre-index no increase in oral glucocorticoid dose during months 6-12 post-index.Injectable glucocorticoid criteria: at most 1 parenteral or intra-articular glucocorticoid joint injection on unique days after participant had been on bDMARD treatment for \>3 months between (index date + 91) to (index date + 365). |
| Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related inpatient visit costs consisted of expenses during hospital visits for formal admission for RA. Outpatient visit costs consisted of expenses when participants visited hospital but not for formal admission for RA. ER visit costs consisted of expenses during visit to ER of hospital for RA. |
| All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause total health care costs, medical costs, pharmacy costs during 12 months post-index period are reported. All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). |
| RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care costs, medical costs, pharmacy costs during 12 months post-index period are reported. RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). |
| Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | Month 1 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 1 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | Month 2 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 2 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | Month 3 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 3 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | Month 4 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 4 of post-index date. |
| Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | Month 5 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 5 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | Month 6 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 6 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | Month 7 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 7 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | Month 8 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 8 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | Month 9 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 9 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | Month 10 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 10 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | Month 11 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 11 post-index date. |
| Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | Month 12 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 12 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | Month 1 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 1 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | Month 2 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measurec RA related total all cause health care cost in dollars is reported for Month 2 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | Month 3 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 3 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | Month 4 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 4 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | Month 5 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 5 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | Month 6 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 6 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | Month 7 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 7 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | Month 8 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 8 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | Month 9 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 9 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | Month 10 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 10 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | Month 11 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 11 post-index date. |
| Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | Month 12 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years) | RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 12 post-index date. |
Countries
United States
Participant flow
Recruitment details
Participants with rheumatoid arthritis (RA), who newly initiated tofacitinib or biologic disease-modifying antirheumatic drug (bDMARDs), between 01 February 2016 and 31 July 2019 (identification period), were identified using Truven Health MarketScan Research database. Data for eligible participants from database were evaluated in this retrospective observational study. Index date = date of first claim for index medication (bDMARDs or tofacitinib) during identification period of 3.5 years.
Pre-assignment details
Baseline characteristics- age, sex, region of enrollment were evaluated at index date. Other study specific characteristics were observed over 12 months before index date (12 months pre-index baseline period) and/or over variable-length pre-index baseline period. Variable-length pre-index baseline period was minimum of 1 year and could have been maximum up to 5.68 years before index date.
Participants by arm
| Arm | Count |
|---|---|
| Tofacitinib XR Participants who started treatment with modified-release (XR) tofacitinib during identification period were included in this arm. | 349 |
| Tofacitinib IR Participants who started treatment with immediate-release (IR) tofacitinib during identification period were included in this arm. | 304 |
| Adalimumab Participants who started treatment with adalimumab (tumor-necrosis factor-alpha inhibitor \[TNFI\]) during identification period were included in this arm. | 2,728 |
| Certolizumab Pegol Participants who started treatment with certolizumab pegol (TNFI) during identification period were included in this arm. | 192 |
| Etanercept Participants who started treatment with etanercept (TNFI) during identification period were included in this arm. | 1,948 |
| Infliximab Participants who started treatment with infliximab (TNFI) during identification period were included in this arm. | 349 |
| Golimumab Participants who started treatment with golimumab (TNFI) during identification period were included in this arm. | 376 |
| Rituximab Participants who started treatment with rituximab (non-TNFI) during identification period were included in this arm. | 325 |
| Tocilizumab Participants who started treatment with tocilizumab (non-TNFI) during identification period were included in this arm. | 204 |
| Abatacept Participants who started treatment with abatacept (non-TNFI) during identification period were included in this arm. | 533 |
| Total | 7,308 |
Baseline characteristics
| Characteristic | Tofacitinib IR | Total | Abatacept | Tocilizumab | Rituximab | Golimumab | Infliximab | Tofacitinib XR | Etanercept | Certolizumab Pegol | Adalimumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 55.93 years STANDARD_DEVIATION 11.26 | 53.14 years STANDARD_DEVIATION 11.3 | 55.88 years STANDARD_DEVIATION 11.45 | 55.99 years STANDARD_DEVIATION 11.65 | 56.13 years STANDARD_DEVIATION 11.9 | 55.63 years STANDARD_DEVIATION 12.55 | 55.85 years STANDARD_DEVIATION 12.33 | 55.48 years STANDARD_DEVIATION 11.04 | 51.85 years STANDARD_DEVIATION 10.89 | 56.70 years STANDARD_DEVIATION 14.9 | 51.42 years STANDARD_DEVIATION 10.35 |
| All cause Inpatient, Outpatient and Emergency Room Visits Costs During 12 Months Pre-Index Period Emergency Room visits costs | 1,404.59 dollars | 1145.23 dollars STANDARD_DEVIATION 3581.14 | 1413.05 dollars STANDARD_DEVIATION 4290.22 | 1721.96 dollars STANDARD_DEVIATION 5667.52 | 1,519.68 dollars STANDARD_DEVIATION 3770.18 | 1014.59 dollars STANDARD_DEVIATION 2993.84 | 1528.22 dollars STANDARD_DEVIATION 3716.98 | 1,308.81 dollars | 1094.48 dollars STANDARD_DEVIATION 3219.72 | 1035.11 dollars STANDARD_DEVIATION 3080.83 | 968.34 dollars STANDARD_DEVIATION 3245.47 |
| All cause Inpatient, Outpatient and Emergency Room Visits Costs During 12 Months Pre-Index Period Inpatient visits costs | 5,918.18 dollars | 4007.49 dollars STANDARD_DEVIATION 18785.55 | 4661.57 dollars STANDARD_DEVIATION 16089.35 | 9475.99 dollars STANDARD_DEVIATION 32796.53 | 10287.84 dollars STANDARD_DEVIATION 32246.91 | 5593.85 dollars STANDARD_DEVIATION 28885.69 | 2802.86 dollars STANDARD_DEVIATION 9813.21 | 6,439.48 dollars | 2908.83 dollars STANDARD_DEVIATION 13624.11 | 5745.63 dollars STANDARD_DEVIATION 21990.52 | 2796.16 dollars STANDARD_DEVIATION 13970.41 |
| All cause Inpatient, Outpatient and Emergency Room Visits Costs During 12 Months Pre-Index Period Outpatient visits costs | 12,056.68 dollars | 10667.28 dollars STANDARD_DEVIATION 20794.73 | 14260.86 dollars STANDARD_DEVIATION 19512.63 | 15879.61 dollars STANDARD_DEVIATION 26952.93 | 25746.57 dollars STANDARD_DEVIATION 46437 | 11200.01 dollars STANDARD_DEVIATION 20002.68 | 13625.70 dollars | 11,764.03 dollars | 8989.76 dollars STANDARD_DEVIATION 18037.61 | 10585.64 dollars STANDARD_DEVIATION 13522.28 | 8235.49 dollars STANDARD_DEVIATION 14916.4 |
| All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Health care costs | 30,416.53 dollars | 21784.90 dollars STANDARD_DEVIATION 36617.83 | 30609.54 dollars STANDARD_DEVIATION 35308.08 | 40490.72 dollars STANDARD_DEVIATION 57253.38 | 48981.85 dollars STANDARD_DEVIATION 75040.93 | 24,401.11 dollars | 23845.95 dollars STANDARD_DEVIATION 30481 | 24,420.92 dollars | 17580.75 dollars STANDARD_DEVIATION 30240.41 | 26501.73 dollars STANDARD_DEVIATION 34187.93 | 16168.53 dollars STANDARD_DEVIATION 25602.71 |
| All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Medical costs | 19,379.45 dollars | 15820.00 dollars STANDARD_DEVIATION 32082.59 | 20335.48 dollars STANDARD_DEVIATION 28896.19 | 27077.56 dollars STANDARD_DEVIATION 48487.39 | 37554.08 dollars STANDARD_DEVIATION 65360.94 | 17808.46 dollars STANDARD_DEVIATION 38710.4 | 17956.78 dollars | 19,512.32 dollars | 12993.07 dollars | 17366.38 dollars STANDARD_DEVIATION 29180.07 | 11999.99 dollars STANDARD_DEVIATION 22939.57 |
| All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Pharmacy costs | 11,037.07 dollars | 5964.90 dollars STANDARD_DEVIATION 14230.43 | 10274.06 dollars STANDARD_DEVIATION 19612.35 | 13413.16 dollars STANDARD_DEVIATION 29104.61 | 11427.76 dollars STANDARD_DEVIATION 33915.6 | 6592.65 dollars STANDARD_DEVIATION 11444.46 | 5889.17 dollars STANDARD_DEVIATION 14361.93 | 4,908.60 dollars | 4587.69 dollars STANDARD_DEVIATION 11199.66 | 9135.35 dollars STANDARD_DEVIATION 13525.45 | 4168.54 dollars STANDARD_DEVIATION 7951.66 |
| Disease Duration During Variable-Length Pre-Index Baseline Period | 919.71 days STANDARD_DEVIATION 437.63 | 648.91 days STANDARD_DEVIATION 504.69 | 789.95 days STANDARD_DEVIATION 498.75 | 806.50 days STANDARD_DEVIATION 527.2 | 888.34 days STANDARD_DEVIATION 541.51 | 651.11 days STANDARD_DEVIATION 482.93 | 661.66 days STANDARD_DEVIATION 513.64 | 882.61 days STANDARD_DEVIATION 558.81 | 568.98 days STANDARD_DEVIATION 474.54 | 730.28 days STANDARD_DEVIATION 536.06 | 570.38 days STANDARD_DEVIATION 481.35 |
| Mean Number of bDMARDs Received During 12 Months Pre-Index Baseline Period | 1.40 number of bDMARDs STANDARD_DEVIATION 0.59 | 1.23 number of bDMARDs STANDARD_DEVIATION 0.49 | 1.22 number of bDMARDs STANDARD_DEVIATION 0.42 | 1.20 number of bDMARDs STANDARD_DEVIATION 0.45 | 1.31 number of bDMARDs STANDARD_DEVIATION 0.62 | 1.19 number of bDMARDs STANDARD_DEVIATION 0.45 | 1.41 number of bDMARDs STANDARD_DEVIATION 0.56 | 1.11 number of bDMARDs STANDARD_DEVIATION 0.32 | 1.06 number of bDMARDs STANDARD_DEVIATION 0.24 | 1.31 number of bDMARDs STANDARD_DEVIATION 0.8 | 1.11 number of bDMARDs STANDARD_DEVIATION 0.31 |
| Mean Number of bDMARDs Received During Variable Length Pre-Index Baseline Period | 1.61 number of bDMARDs STANDARD_DEVIATION 0.81 | 1.55 number of bDMARDs STANDARD_DEVIATION 0.87 | 1.58 number of bDMARDs STANDARD_DEVIATION 0.78 | 1.79 number of bDMARDs STANDARD_DEVIATION 0.95 | 1.78 number of bDMARDs STANDARD_DEVIATION 1.14 | 1.58 number of bDMARDs STANDARD_DEVIATION 0.91 | 1.83 number of bDMARDs STANDARD_DEVIATION 1.09 | 1.46 number of bDMARDs STANDARD_DEVIATION 0.73 | 1.23 number of bDMARDs STANDARD_DEVIATION 0.65 | 1.88 number of bDMARDs STANDARD_DEVIATION 1.12 | 1.24 number of bDMARDs STANDARD_DEVIATION 0.55 |
| Mean Number of csDMARDs Received During 12 Months Pre-Index Baseline Period | 1.48 csDMARDs STANDARD_DEVIATION 0.66 | 1.57 csDMARDs STANDARD_DEVIATION 0.7 | 1.63 csDMARDs STANDARD_DEVIATION 0.73 | 1.49 csDMARDs STANDARD_DEVIATION 0.69 | 1.56 csDMARDs STANDARD_DEVIATION 0.68 | 1.50 csDMARDs STANDARD_DEVIATION 0.67 | 1.56 csDMARDs STANDARD_DEVIATION 0.72 | 1.58 csDMARDs STANDARD_DEVIATION 0.66 | 1.61 csDMARDs STANDARD_DEVIATION 0.72 | 1.39 csDMARDs STANDARD_DEVIATION 0.59 | 1.56 csDMARDs STANDARD_DEVIATION 0.69 |
| Mean Number of csDMARDs Received During Variable Length Pre-Index Baseline Period | 1.88 csDMARDs STANDARD_DEVIATION 0.87 | 1.81 csDMARDs | 2.02 csDMARDs STANDARD_DEVIATION 0.92 | 1.71 csDMARDs STANDARD_DEVIATION 0.88 | 1.93 csDMARDs STANDARD_DEVIATION 0.91 | 1.73 csDMARDs STANDARD_DEVIATION 0.82 | 1.76 csDMARDs STANDARD_DEVIATION 0.86 | 1.91 csDMARDs STANDARD_DEVIATION 0.89 | 1.82 csDMARDs STANDARD_DEVIATION 0.85 | 1.66 csDMARDs STANDARD_DEVIATION 0.8 | 1.76 csDMARDs STANDARD_DEVIATION 0.82 |
| Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Pre-Index Baseline Period | 5.31 pharmacy claims STANDARD_DEVIATION 6.85 | 4.35 pharmacy claims STANDARD_DEVIATION 5.89 | 4.58 pharmacy claims STANDARD_DEVIATION 5.94 | 5.05 pharmacy claims STANDARD_DEVIATION 6.21 | 4.14 pharmacy claims STANDARD_DEVIATION 5.23 | 4.46 pharmacy claims STANDARD_DEVIATION 5.38 | 4.84 pharmacy claims STANDARD_DEVIATION 5.92 | 4.04 pharmacy claims STANDARD_DEVIATION 6.39 | 4.45 pharmacy claims STANDARD_DEVIATION 5.8 | 4.15 pharmacy claims STANDARD_DEVIATION 6.09 | 4.08 pharmacy claims STANDARD_DEVIATION 5.84 |
| Mean Number of Visits to Rheumatologist During 12 Months Pre-Index Baseline Period | 4.92 visits STANDARD_DEVIATION 2.9 | 4.97 visits STANDARD_DEVIATION 2.89 | 5.92 visits STANDARD_DEVIATION 4.19 | 5.79 visits STANDARD_DEVIATION 3.94 | 5.41 visits STANDARD_DEVIATION 3.06 | 5.89 visits STANDARD_DEVIATION 3.59 | 5.60 visits STANDARD_DEVIATION 2.88 | 4.53 visits STANDARD_DEVIATION 2.38 | 4.76 visits STANDARD_DEVIATION 2.62 | 5.26 visits STANDARD_DEVIATION 2.88 | 4.65 visits STANDARD_DEVIATION 2.47 |
| Mean Number of Visits to Rheumatologist During Variable-Length Pre-Index Baseline Period | 12.12 visits STANDARD_DEVIATION 8.56 | 9.61 visits STANDARD_DEVIATION 7.45 | 12.43 visits STANDARD_DEVIATION 8.9 | 13.75 visits STANDARD_DEVIATION 11.8 | 13.01 visits STANDARD_DEVIATION 9.69 | 11.25 visits STANDARD_DEVIATION 8.36 | 10.79 visits STANDARD_DEVIATION 7.79 | 11.28 visits STANDARD_DEVIATION 8.45 | 8.39 visits STANDARD_DEVIATION 6.03 | 11.43 visits STANDARD_DEVIATION 9.51 | 8.21 visits STANDARD_DEVIATION 5.98 |
| Number of Participants Who Used Opioids or NSAIDs During 12 Months Pre-Index Baseline Period | 236 Participants | 5119 Participants | 380 Participants | 157 Participants | 229 Participants | 277 Participants | 265 Participants | 214 Participants | 1,360 Participants | 134 Participants | 1,867 Participants |
| Number of Participants Who Used Oral Corticosteroids During 12 Months Pre-Index Baseline Period | 222 Participants | 5635 Participants | 400 Participants | 167 Participants | 249 Participants | 280 Participants | 276 Participants | 254 Participants | 1,515 Participants | 134 Participants | 2,138 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Anxiety | 57 Participants | 1187 Participants | 98 Participants | 18 Participants | 50 Participants | 58 Participants | 60 Participants | 59 Participants | 343 Participants | 32 Participants | 412 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Asthma | 38 Participants | 778 Participants | 71 Participants | 26 Participants | 35 Participants | 30 Participants | 45 Participants | 35 Participants | 210 Participants | 16 Participants | 272 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Cardiovascular disease | 189 Participants | 3888 Participants | 328 Participants | 133 Participants | 210 Participants | 208 Participants | 205 Participants | 198 Participants | 992 Participants | 110 Participants | 1315 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period COPD | 33 Participants | 764 Participants | 74 Participants | 34 Participants | 47 Participants | 38 Participants | 46 Participants | 33 Participants | 188 Participants | 23 Participants | 248 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Depression | 58 Participants | 1305 Participants | 117 Participants | 35 Participants | 58 Participants | 67 Participants | 60 Participants | 54 Participants | 376 Participants | 30 Participants | 450 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Diabetes | 54 Participants | 1178 Participants | 114 Participants | 33 Participants | 62 Participants | 56 Participants | 65 Participants | 54 Participants | 283 Participants | 33 Participants | 424 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Hyperlipidemia | 120 Participants | 2684 Participants | 223 Participants | 88 Participants | 115 Participants | 147 Participants | 155 Participants | 150 Participants | 682 Participants | 73 Participants | 931 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Hypertension | 153 Participants | 3120 Participants | 268 Participants | 104 Participants | 158 Participants | 172 Participants | 169 Participants | 157 Participants | 790 Participants | 96 Participants | 1053 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Kidney disease | 30 Participants | 790 Participants | 81 Participants | 30 Participants | 55 Participants | 43 Participants | 38 Participants | 37 Participants | 192 Participants | 27 Participants | 257 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Liver disease | 17 Participants | 440 Participants | 41 Participants | 19 Participants | 31 Participants | 19 Participants | 24 Participants | 18 Participants | 111 Participants | 17 Participants | 143 Participants |
| Number of Participants With Comorbidities of Interest During 12 Months Pre-Index Baseline Period Sleep disorders | 31 Participants | 842 Participants | 79 Participants | 26 Participants | 34 Participants | 49 Participants | 45 Participants | 44 Participants | 209 Participants | 18 Participants | 307 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Acetaminophen/Hydrocodone Bitartrate | 89 Participants | 2092 Participants | 157 Participants | 75 Participants | 107 Participants | 114 Participants | 122 Participants | 82 Participants | 518 Participants | 60 Participants | 768 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Acetaminophen/Oxycodone Hydrochloride | 39 Participants | 885 Participants | 82 Participants | 32 Participants | 49 Participants | 41 Participants | 56 Participants | 40 Participants | 229 Participants | 23 Participants | 294 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Albuterol Sulfate | 48 Participants | 1089 Participants | 92 Participants | 36 Participants | 47 Participants | 42 Participants | 54 Participants | 52 Participants | 282 Participants | 25 Participants | 411 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Amoxicillin | 41 Participants | 1048 Participants | 94 Participants | 29 Participants | 47 Participants | 62 Participants | 47 Participants | 52 Participants | 286 Participants | 25 Participants | 365 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Amoxicillin/Clavulanate Potassium | 34 Participants | 957 Participants | 80 Participants | 28 Participants | 40 Participants | 36 Participants | 52 Participants | 60 Participants | 228 Participants | 19 Participants | 380 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Atorvastatin Calcium | 26 Participants | 793 Participants | 64 Participants | 29 Participants | 33 Participants | 41 Participants | 51 Participants | 54 Participants | 190 Participants | 20 Participants | 285 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Azithromycin | 64 Participants | 1624 Participants | 126 Participants | 38 Participants | 67 Participants | 94 Participants | 74 Participants | 89 Participants | 430 Participants | 50 Participants | 592 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Ciprofloxacin Hydrochloride | 38 Participants | 800 Participants | 80 Participants | 23 Participants | 52 Participants | 42 Participants | 41 Participants | 40 Participants | 219 Participants | 16 Participants | 249 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Cyclobenzaprine Hydrochloride | 43 Participants | 1015 Participants | 73 Participants | 35 Participants | 40 Participants | 55 Participants | 45 Participants | 46 Participants | 286 Participants | 25 Participants | 367 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Diclofenac Sodium | 42 Participants | 1085 Participants | 77 Participants | 28 Participants | 34 Participants | 64 Participants | 62 Participants | 47 Participants | 294 Participants | 27 Participants | 410 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Duloxetine Hydrochloride | 34 Participants | 834 Participants | 75 Participants | 28 Participants | 30 Participants | 51 Participants | 47 Participants | 36 Participants | 222 Participants | 22 Participants | 289 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Ergocalciferol | 32 Participants | 853 Participants | 60 Participants | 28 Participants | 36 Participants | 56 Participants | 40 Participants | 48 Participants | 206 Participants | 25 Participants | 322 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Fluticasone Propionate | 51 Participants | 962 Participants | 70 Participants | 25 Participants | 47 Participants | 46 Participants | 51 Participants | 55 Participants | 259 Participants | 29 Participants | 329 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Folic Acid | 177 Participants | 5138 Participants | 329 Participants | 122 Participants | 197 Participants | 272 Participants | 230 Participants | 226 Participants | 1,435 Participants | 126 Participants | 2,024 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Gabapentin | 34 Participants | 1137 Participants | 114 Participants | 37 Participants | 53 Participants | 64 Participants | 64 Participants | 52 Participants | 315 Participants | 31 Participants | 373 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Hydroxychloroquine Sulfate | 98 Participants | 2470 Participants | 211 Participants | 59 Participants | 112 Participants | 109 Participants | 102 Participants | 106 Participants | 711 Participants | 43 Participants | 919 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Ibuprofen | 40 Participants | 874 Participants | 62 Participants | 27 Participants | 29 Participants | 50 Participants | 59 Participants | 36 Participants | 233 Participants | 20 Participants | 318 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Leflunomide | 50 Participants | 1059 Participants | 94 Participants | 27 Participants | 44 Participants | 62 Participants | 60 Participants | 56 Participants | 283 Participants | 27 Participants | 356 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Levothyroxine Sodium | 55 Participants | 1380 Participants | 119 Participants | 43 Participants | 62 Participants | 73 Participants | 65 Participants | 67 Participants | 363 Participants | 35 Participants | 498 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Meloxicam | 47 Participants | 1550 Participants | 89 Participants | 36 Participants | 41 Participants | 81 Participants | 73 Participants | 59 Participants | 448 Participants | 29 Participants | 647 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Methotrexate Sodium | 220 Participants | 6246 Participants | 396 Participants | 152 Participants | 253 Participants | 313 Participants | 306 Participants | 279 Participants | 1,732 Participants | 155 Participants | 2440 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Methylprednisolone | 61 Participants | 1738 Participants | 112 Participants | 39 Participants | 52 Participants | 89 Participants | 81 Participants | 79 Participants | 503 Participants | 38 Participants | 684 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Omeprazole | 50 Participants | 1124 Participants | 92 Participants | 40 Participants | 67 Participants | 62 Participants | 62 Participants | 42 Participants | 320 Participants | 22 Participants | 367 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Prednisone | 203 Participants | 5112 Participants | 368 Participants | 157 Participants | 232 Participants | 251 Participants | 250 Participants | 219 Participants | 1,379 Participants | 123 Participants | 1,930 Participants |
| Number of Participants With Most Commonly Used Medications During 12 Month Pre-index Baseline Period Tramadol Hydrochloride | 64 Participants | 1645 Participants | 124 Participants | 44 Participants | 84 Participants | 89 Participants | 79 Participants | 58 Participants | 462 Participants | 37 Participants | 604 Participants |
| Out of Pocket Health Care Costs for Healthcare Services During 12 Months Pre-Index Baseline Period | 2154.86 dollars STANDARD_DEVIATION 1828.01 | 2217.74 dollars STANDARD_DEVIATION 1931.29 | 2453.28 dollars STANDARD_DEVIATION 2389.53 | 2174.18 dollars STANDARD_DEVIATION 1553.37 | 2797.43 dollars STANDARD_DEVIATION 2975.36 | 2174.31 dollars STANDARD_DEVIATION 1782.74 | 2287.63 dollars STANDARD_DEVIATION 2494.77 | 1803.44 dollars STANDARD_DEVIATION 1789.99 | 2251.93 dollars STANDARD_DEVIATION 1800.59 | 2013.10 dollars STANDARD_DEVIATION 1714.01 | 2152.95 dollars STANDARD_DEVIATION 1741.99 |
| Out of Pocket Health Care Costs for Healthcare Services During Variable Length Pre-Index Period | 6549.23 dollars STANDARD_DEVIATION 4717.18 | 6672.79 dollars STANDARD_DEVIATION 6042.9 | 7636.47 dollars STANDARD_DEVIATION 6096.75 | 7331.39 dollars STANDARD_DEVIATION 5037.3 | 8934.99 dollars STANDARD_DEVIATION 12740.35 | 6841.01 dollars STANDARD_DEVIATION 6423.2 | 6856.14 dollars STANDARD_DEVIATION 6946.33 | 6626.03 dollars STANDARD_DEVIATION 5819.96 | 6510.77 dollars STANDARD_DEVIATION 5550.34 | 6453.01 dollars STANDARD_DEVIATION 5204.02 | 6270.02 dollars STANDARD_DEVIATION 5087.71 |
| Quan-Charlson Comorbidity Score During 12 Months Pre-Index Baseline Period | 1.89 units on a scale STANDARD_DEVIATION 1.32 | 1.78 units on a scale STANDARD_DEVIATION 1.23 | 2.10 units on a scale STANDARD_DEVIATION 1.46 | 2.01 units on a scale STANDARD_DEVIATION 1.52 | 2.54 units on a scale STANDARD_DEVIATION 1.81 | 1.72 units on a scale STANDARD_DEVIATION 1.22 | 1.94 units on a scale STANDARD_DEVIATION 1.43 | 1.77 units on a scale STANDARD_DEVIATION 1.14 | 1.70 units on a scale STANDARD_DEVIATION 1.13 | 1.95 units on a scale STANDARD_DEVIATION 1.46 | 1.63 units on a scale STANDARD_DEVIATION 1.04 |
| Race and Ethnicity Not Collected | — | 0 Participants | — | — | — | — | — | — | — | — | — |
| RA Related Inpatient, Outpatient and ER Visits Costs During 12 Months Pre-Index Baseline Period ER visits costs | 328.19 dollars | 273.51 dollars STANDARD_DEVIATION 1411.57 | 365.98 dollars STANDARD_DEVIATION 1593.09 | 363.43 dollars STANDARD_DEVIATION 1481.07 | 399.12 dollars STANDARD_DEVIATION 1739.26 | 212.55 dollars STANDARD_DEVIATION 1251.78 | 407.85 dollars STANDARD_DEVIATION 1947.66 | 349.64 dollars | 259.28 dollars STANDARD_DEVIATION 1316.71 | 277.53 dollars STANDARD_DEVIATION 2140.86 | 219.03 dollars STANDARD_DEVIATION 1206.08 |
| RA Related Inpatient, Outpatient and ER Visits Costs During 12 Months Pre-Index Baseline Period Inpatient visits cost | 2,831.70 dollars | 1791.46 dollars STANDARD_DEVIATION 10793.1 | 2353.90 dollars STANDARD_DEVIATION 12328.42 | 3468.19 dollars STANDARD_DEVIATION 15523.54 | 4505.60 dollars STANDARD_DEVIATION 20528.63 | 1838.26 dollars STANDARD_DEVIATION 12154.86 | 1309.07 dollars STANDARD_DEVIATION 6851.41 | 3,089.94 dollars | 1587.91 dollars STANDARD_DEVIATION 9792.03 | 1789.30 dollars STANDARD_DEVIATION 8142.05 | 1151.57 dollars STANDARD_DEVIATION 7901.71 |
| RA Related Inpatient, Outpatient and ER Visits Costs During 12 Months Pre-Index Baseline Period Outpatient visits costs | 3,062.35 dollars | 2467.90 dollars STANDARD_DEVIATION 8644.57 | 3272.09 dollars STANDARD_DEVIATION 8075.92 | 4237.16 dollars STANDARD_DEVIATION 13758.63 | 5363.37 dollars STANDARD_DEVIATION 11254.35 | 2601.07 dollars STANDARD_DEVIATION 11012.98 | 5686.02 dollars STANDARD_DEVIATION 19928.57 | 4,006.13 dollars | 1665.28 dollars STANDARD_DEVIATION 2716.01 | 2263.77 dollars STANDARD_DEVIATION 6164.69 | 1727.93 dollars STANDARD_DEVIATION 3936.67 |
| RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Health care costs | 14,943.61 dollars | 7230.81 dollars | 11914.79 dollars | 15136.67 dollars STANDARD_DEVIATION 23086.46 | 15878.07 dollars STANDARD_DEVIATION 31575.28 | 8151.85 dollars STANDARD_DEVIATION 18490.62 | 10462.36 dollars STANDARD_DEVIATION 22548.83 | 8,833.52 dollars | 4935.77 dollars STANDARD_DEVIATION 11793.45 | 9807.20 dollars STANDARD_DEVIATION 15314.26 | 4546.86 dollars STANDARD_DEVIATION 10379.97 |
| RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Medical costs | 6,222.23 dollars | 4,532.88 dollars | 5,991.97 dollars | 8068.79 dollars STANDARD_DEVIATION 20919.77 | 10268.09 dollars STANDARD_DEVIATION 24816.89 | 4651.88 dollars STANDARD_DEVIATION 16484.62 | 7402.94 dollars STANDARD_DEVIATION 21149.65 | 7,445.71 dollars | 3512.47 dollars STANDARD_DEVIATION 10696.1 | 4330.60 dollars STANDARD_DEVIATION 10538.65 | 3098.53 dollars STANDARD_DEVIATION 9170.64 |
| RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Pre-Index Period Pharmacy costs | 7,230.13 dollars | 2,211.73 dollars | 4,434.95 dollars | 5537.26 dollars STANDARD_DEVIATION 11303.84 | 3413.49 dollars STANDARD_DEVIATION 9249.18 | 2399.30 dollars STANDARD_DEVIATION 6306.26 | 2272.80 dollars STANDARD_DEVIATION 6908.41 | 1,215.71 dollars | 1347.30 dollars STANDARD_DEVIATION 4566.96 | 4712.28 dollars STANDARD_DEVIATION 11103.97 | 1361.31 dollars STANDARD_DEVIATION 4448.33 |
| Region of Enrollment United States North Central Region | 58 Participants | 1463 Participants | 93 Participants | 37 Participants | 77 Participants | 46 Participants | 74 Participants | 62 Participants | 390 Participants | 21 Participants | 605 Participants |
| Region of Enrollment United States Northeast Region | 69 Participants | 1281 Participants | 114 Participants | 41 Participants | 57 Participants | 55 Participants | 51 Participants | 96 Participants | 331 Participants | 45 Participants | 422 Participants |
| Region of Enrollment United States South Region | 137 Participants | 3571 Participants | 256 Participants | 97 Participants | 120 Participants | 235 Participants | 178 Participants | 143 Participants | 952 Participants | 104 Participants | 1349 Participants |
| Region of Enrollment United States Unknown Region | 0 Participants | 11 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 4 Participants |
| Region of Enrollment United States West Region | 40 Participants | 982 Participants | 70 Participants | 29 Participants | 71 Participants | 37 Participants | 46 Participants | 45 Participants | 274 Participants | 22 Participants | 348 Participants |
| Sex: Female, Male Female | 250 Participants | 5779 Participants | 448 Participants | 158 Participants | 257 Participants | 302 Participants | 279 Participants | 282 Participants | 1523 Participants | 156 Participants | 2124 Participants |
| Sex: Female, Male Male | 54 Participants | 1529 Participants | 85 Participants | 46 Participants | 68 Participants | 74 Participants | 70 Participants | 67 Participants | 425 Participants | 36 Participants | 604 Participants |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 1 | 1,585.23 dollars | 1,545.44 dollars | 1,697.90 dollars | 2,578.36 dollars | 5,422.21 dollars | 1,654.98 dollars | 1,223.86 dollars | 1,472.00 dollars | 1,309.62 dollars | 1,268.10 dollars | 1,195.47 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 10 | 2,471.86 dollars | 1,936.48 dollars | 2,729.46 dollars | 4,993.31 dollars | 3,353.37 dollars | 2,275.94 dollars | 2,320.68 dollars | 2,255.16 dollars | 1,504.17 dollars | 2,441.32 dollars | 1,460.94 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 11 | 2,789.28 dollars | 1,839.75 dollars | 2,705.38 dollars | 2,986.24 dollars | 3,795.88 dollars | 2,574.77 dollars | 1,886.96 dollars | 2,531.08 dollars | 1,503.62 dollars | 1,584.63 dollars | 1,308.22 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 12 | 3,128.29 dollars | 1,794.44 dollars | 2,845.43 dollars | 2,973.41 dollars | 4,211.34 dollars | 1,858.76 dollars | 1,829.55 dollars | 2,370.10 dollars | 1,391.97 dollars | 3,126.35 dollars | 1,171.01 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 2 | 1,893.55 dollars | 1,611.54 dollars | 1,967.35 dollars | 2,988.66 dollars | 4,457.43 dollars | 1,582.17 dollars | 1,800.75 dollars | 1,841.98 dollars | 1,358.67 dollars | 1,302.98 dollars | 1,221.22 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 3 | 1,967.88 dollars | 1,778.72 dollars | 2,568.07 dollars | 3,142.42 dollars | 4,999.71 dollars | 1,456.25 dollars | 1,945.43 dollars | 1,950.72 dollars | 1,344.95 dollars | 1,991.21 dollars | 1,413.62 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 4 | 2,345.62 dollars | 1,833.05 dollars | 2,548.52 dollars | 3,468.91 dollars | 3,173.71 dollars | 2,512.04 dollars | 2,147.16 dollars | 1,831.75 dollars | 1,505.32 dollars | 2,483.09 dollars | 1,408.75 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 5 | 3,392.53 dollars | 1,950.09 dollars | 2,808.88 dollars | 2,948.97 dollars | 4,185.96 dollars | 2,218.34 dollars | 2,114.46 dollars | 1,675.13 dollars | 1,591.72 dollars | 1,758.14 dollars | 1,527.09 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 6 | 2,872.44 dollars | 1,841.56 dollars | 2,314.86 dollars | 3,514.88 dollars | 4,055.38 dollars | 1,917.33 dollars | 2,072.51 dollars | 1,795.34 dollars | 1,494.42 dollars | 2,739.15 dollars | 1,395.97 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 7 | 2,748.68 dollars | 1,918.63 dollars | 3,161.07 dollars | 2,888.53 dollars | 3,973.03 dollars | 1,853.74 dollars | 2,300.37 dollars | 2,065.20 dollars | 1,613.11 dollars | 3,155.53 dollars | 1,338.57 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 8 | 2,573.90 dollars | 1,899.12 dollars | 2,907.13 dollars | 4,544.99 dollars | 3,345.52 dollars | 2,276.07 dollars | 1,979.07 dollars | 1,821.27 dollars | 1,494.05 dollars | 2,851.54 dollars | 1,426.81 dollars |
| Total All Cause Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 9 | 2,647.26 dollars | 1,836.07 dollars | 2,355.49 dollars | 3,462.03 dollars | 4,008.30 dollars | 2,220.71 dollars | 2,225.15 dollars | 2,811.19 dollars | 1,469.14 dollars | 1,799.68 dollars | 1,300.85 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 1 | 703.28 dollars | 528.95 dollars | 473.64 dollars | 430.25 dollars | 1,962.14 dollars | 539.47 dollars | 441.39 dollars | 406.83 dollars | 469.85 dollars | 322.11 dollars STANDARD_DEVIATION 844.32 | 439.11 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 10 | 1,202.02 dollars | 533.13 dollars | 1,217.53 dollars | 2,010.47 dollars | 962.51 dollars | 518.84 dollars | 877.15 dollars | 840.51 dollars | 248.11 dollars | 618.40 dollars | 279.40 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 11 | 1,742.02 dollars | 576.61 dollars | 1,129.36 dollars | 1,078.26 dollars | 999.43 dollars | 663.43 dollars | 732.68 dollars | 792.87 dollars | 321.38 dollars | 635.71 dollars | 369.35 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 12 | 1,513.38 dollars | 572.10 dollars | 946.24 dollars | 1,404.77 dollars | 1,481.59 dollars | 523.41 dollars | 636.49 dollars | 866.68 dollars | 428.33 dollars | 1,154.62 dollars | 245.94 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 2 | 882.34 dollars | 578.64 dollars | 654.37 dollars | 1,325.06 dollars | 1,192.36 dollars | 549.71 dollars | 928.87 dollars | 566.83 dollars | 431.85 dollars | 531.40 dollars | 469.92 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 3 | 1,056.77 dollars | 630.44 dollars | 921.59 dollars | 1,020.45 dollars | 1,649.74 dollars | 560.10 dollars | 756.09 dollars | 655.66 dollars | 456.38 dollars | 1,142.03 dollars | 454.12 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 4 | 1,303.00 dollars | 662.62 dollars | 1,119.77 dollars | 1,277.46 dollars | 757.71 dollars | 1,202.34 dollars | 958.05 dollars | 730.91 dollars | 482.37 dollars | 798.63 dollars | 442.85 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 5 | 1,062.30 dollars | 666.50 dollars | 825.12 dollars | 1,164.43 dollars | 1,273.15 dollars | 1,048.93 dollars | 954.68 dollars | 685.73 dollars | 521.77 dollars | 765.62 dollars | 486.22 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 6 | 1,153.03 dollars | 621.82 dollars | 886.98 dollars | 1,512.57 dollars | 1,336.14 dollars | 683.35 dollars | 1,179.18 dollars | 660.86 dollars | 420.73 dollars | 1,149.35 dollars | 380.78 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 7 | 1,595.90 dollars | 643.43 dollars | 1,506.72 dollars | 1,580.73 dollars | 1,535.64 dollars | 528.57 dollars | 1,043.14 dollars | 795.24 dollars | 371.06 dollars | 1,084.32 dollars | 300.98 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 8 | 1,562.50 dollars | 612.85 dollars | 1,276.16 dollars | 1,179.40 dollars | 1,164.74 dollars | 860.95 dollars | 954.47 dollars | 684.64 dollars | 335.36 dollars | 976.85 dollars | 354.75 dollars |
| Total RA Related Monthly Health Care Cost During 12 Months Pre-Index Baseline Period Month 9 | 1,167.06 dollars | 603.72 dollars | 957.33 dollars | 1,152.80 dollars | 1,562.92 dollars | 472.76 dollars | 1,000.19 dollars | 1,146.75 dollars | 448.58 dollars | 628.15 dollars | 323.44 dollars |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy
Participants with monotherapy who used additional csDMARD during post index period are reported.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study. Here, overall number of participants analyzed signifies the participants who initiated treatment as monotherapy with index medication only.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 48 Participants |
| Tofacitinib IR | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 37 Participants |
| Adalimumab | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 247 Participants |
| Certolizumab Pegol | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 29 Participants |
| Etanercept | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 193 Participants |
| Infliximab | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 28 Participants |
| Golimumab | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 31 Participants |
| Rituximab | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 39 Participants |
| Tocilizumab | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 36 Participants |
| Abatacept | Addition of Conventional Synthetic Disease-modifying Antirheumatic Drug (Cs-DMARDs) in Participants With Monotherapy | 70 Participants |
Primary
Adherence to Cs-DMARDs in Participants With Combination Therapy
Adherence was calculated as the total day supply for csDMARDs divided by the number of days from the first claim during the follow-up until the end of the follow-up.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study. Here, overall number of participants analyzed signifies the participants who initiated treatment as combination therapy with index medication and cs-DMARDs.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib XR | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.72 ratio | Standard Deviation 0.3 |
| Tofacitinib IR | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.79 ratio | Standard Deviation 0.26 |
| Adalimumab | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.77 ratio | Standard Deviation 0.27 |
| Certolizumab Pegol | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.74 ratio | Standard Deviation 0.28 |
| Etanercept | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.78 ratio | Standard Deviation 0.27 |
| Infliximab | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.79 ratio | Standard Deviation 0.26 |
| Golimumab | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.79 ratio | Standard Deviation 0.27 |
| Rituximab | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.77 ratio | Standard Deviation 0.28 |
| Tocilizumab | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.70 ratio | Standard Deviation 0.3 |
| Abatacept | Adherence to Cs-DMARDs in Participants With Combination Therapy | 0.80 ratio | Standard Deviation 0.26 |
Primary
All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period
All cause inpatient visits costs, outpatient visits costs and emergency room visits costs during 12 months post index period are reported. Inpatient visit costs consisted of expenses during hospital visit for formal admission. Outpatient visit costs consisted of expenses when participants visited hospital but not for formal admission. Emergency room visit costs consisted of expenses during visit to hospital emergency room.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Tofacitinib XR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 5,301.85 dollars |
| Tofacitinib XR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,330.49 dollars |
| Tofacitinib XR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 11,533.02 dollars |
| Tofacitinib IR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 10,643.90 dollars |
| Tofacitinib IR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,500.08 dollars |
| Tofacitinib IR | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 4,326.53 dollars |
| Adalimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,079.34 dollars |
| Adalimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 3,863.95 dollars |
| Adalimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 9,477.87 dollars |
| Certolizumab Pegol | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,738.59 dollars |
| Certolizumab Pegol | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 4,691.74 dollars |
| Certolizumab Pegol | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 33,271.44 dollars |
| Etanercept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 3,856.57 dollars |
| Etanercept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 10,567.29 dollars |
| Etanercept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,176.85 dollars |
| Infliximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 42,056.44 dollars |
| Infliximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 5,260.88 dollars |
| Infliximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,663.83 dollars |
| Golimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 3,482.13 dollars |
| Golimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,177.78 dollars |
| Golimumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 39,161.11 dollars |
| Rituximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 69,689.17 dollars |
| Rituximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 11,204.53 dollars |
| Rituximab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,787.39 dollars |
| Tocilizumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 28,394.20 dollars |
| Tocilizumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 5,929.53 dollars |
| Tocilizumab | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,567.34 dollars |
| Abatacept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 5,995.50 dollars |
| Abatacept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 1,814.41 dollars |
| Abatacept | All Cause Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 35,119.77 dollars |
Primary
All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period
All cause total health care costs, medical costs, pharmacy costs during 12 months post-index period are reported. All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs).
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Tofacitinib XR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 61,431.53 dollars |
| Tofacitinib XR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 43,266.17 dollars |
| Tofacitinib XR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 18,165.35 dollars |
| Tofacitinib IR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 16,470.52 dollars |
| Tofacitinib IR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 36,680.40 dollars |
| Tofacitinib IR | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 53,150.92 dollars |
| Adalimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 52,224.02 dollars |
| Adalimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 66,645.17 dollars |
| Adalimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 14,421.15 dollars |
| Certolizumab Pegol | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 22,362.45 dollars |
| Certolizumab Pegol | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 62,064.23 dollars |
| Certolizumab Pegol | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 39,701.78 dollars |
| Etanercept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 64,120.91 dollars |
| Etanercept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 15,600.71 dollars |
| Etanercept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 48,520.21 dollars |
| Infliximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 48,981.15 dollars |
| Infliximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 55,737.03 dollars |
| Infliximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 6,755.88 dollars |
| Golimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 58,148.31 dollars |
| Golimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 14,327.29 dollars |
| Golimumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 43,821.02 dollars |
| Rituximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 82,681.09 dollars |
| Rituximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 95,365.52 dollars |
| Rituximab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 12,684.43 dollars |
| Tocilizumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 35,891.07 dollars |
| Tocilizumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 62,120.81 dollars |
| Tocilizumab | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 26,229.74 dollars |
| Abatacept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 69,508.99 dollars |
| Abatacept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 26,579.30 dollars |
| Abatacept | All Cause Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 42,929.69 dollars |
Primary
Mean Medication Possession Ratio (MPR) for Methotrexate
MPR was calculated as the total days supply of methotrexate between the first and including the last prescription/administration divided by the time between the first through and including last biologic prescription/administration days supply.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study. As per planned analysis MPR was not evaluated for Rituximab arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib XR | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.89 ratio | Standard Deviation 0.16 |
| Tofacitinib IR | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.87 ratio | Standard Deviation 0.18 |
| Adalimumab | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.91 ratio | Standard Deviation 0.14 |
| Certolizumab Pegol | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.92 ratio | Standard Deviation 0.14 |
| Etanercept | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.91 ratio | Standard Deviation 0.14 |
| Infliximab | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.98 ratio | Standard Deviation 0.07 |
| Golimumab | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.65 ratio | Standard Deviation 0.18 |
| Tocilizumab | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.89 ratio | Standard Deviation 0.14 |
| Abatacept | Mean Medication Possession Ratio (MPR) for Methotrexate | 0.91 ratio | Standard Deviation 0.14 |
Primary
Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period
Mean number of days from the index date to the first opioid and NSAIDs claim during post index period are reported.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study. Here, overall number of participants analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tofacitinib XR | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 116.22 days | Standard Deviation 99.95 |
| Tofacitinib XR | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 85.35 days | Standard Deviation 94.49 |
| Tofacitinib IR | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 83.31 days | Standard Deviation 95.78 |
| Tofacitinib IR | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 99.94 days | Standard Deviation 95.31 |
| Adalimumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 107.03 days | Standard Deviation 99.29 |
| Adalimumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 95.67 days | Standard Deviation 98.71 |
| Certolizumab Pegol | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 99.05 days | Standard Deviation 105.2 |
| Certolizumab Pegol | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 123.31 days | Standard Deviation 106.32 |
| Etanercept | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 94.05 days | Standard Deviation 99.55 |
| Etanercept | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 105.37 days | Standard Deviation 97.93 |
| Infliximab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 118.44 days | Standard Deviation 107.09 |
| Infliximab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 101.04 days | Standard Deviation 102.35 |
| Golimumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 88.81 days | Standard Deviation 89.79 |
| Golimumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 110.65 days | Standard Deviation 103.11 |
| Rituximab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 98.71 days | Standard Deviation 101.38 |
| Rituximab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 97.37 days | Standard Deviation 92.35 |
| Tocilizumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 81.58 days | Standard Deviation 92.36 |
| Tocilizumab | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 92.44 days | Standard Deviation 89.42 |
| Abatacept | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First Opioid | 93.31 days | Standard Deviation 96.62 |
| Abatacept | Mean Number of Days From The Index Date to the First Opioid and NSAIDs Claim During 12 Months Post Index Period | Days to First NSAID | 90.89 days | Standard Deviation 93.8 |
Primary
Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period
The mean number of pharmacy claims for opioids and NSAIDs during the post-index period are reported. A pharmacy claim was defined as a claim made by participants to their insurance provider in purchasing opioids and NSAIDs from the pharmacy.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study. Here, overall number of participants analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib XR | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 3.68 pharmacy claims | Standard Deviation 6.04 |
| Tofacitinib IR | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 4.99 pharmacy claims | Standard Deviation 6.87 |
| Adalimumab | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 3.78 pharmacy claims | Standard Deviation 5.98 |
| Certolizumab Pegol | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 3.80 pharmacy claims | Standard Deviation 6 |
| Etanercept | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 4.13 pharmacy claims | Standard Deviation 6 |
| Infliximab | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 4.30 pharmacy claims | Standard Deviation 6.04 |
| Golimumab | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 4.08 pharmacy claims | Standard Deviation 5.37 |
| Rituximab | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 3.83 pharmacy claims | Standard Deviation 5.63 |
| Tocilizumab | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 5.19 pharmacy claims | Standard Deviation 6.52 |
| Abatacept | Mean Number of Pharmacy Claims for Opioids and NSAIDS During 12 Months Post Index Period | 4.50 pharmacy claims | Standard Deviation 6.23 |
Primary
Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date
Number of participants with most commonly used medications use during 12 months post index period are reported. The 25 most medications: 1) methotrexate sodium, 2) prednisone, 3) folic acid, 4) adalimumab, 5) etanercept, 6) acetaminophen/hydrocodone bitartrate, 7) hydroxychloroquine sulfate, 8) azithromycin, 9) levothyroxine sodium, 10) tramadol hydrochloride, 11) methylprednisolone, 12) gabapentin, 13) albuterol sulfate, 14) amoxicillin/clavulanate potassium, 15) omeprazole, 16) amoxicillin, 17) meloxicam, 18) tofacitinib citrate, 19) fluticasone propionate, 20) cyclobenzaprine hydrochloride, 21) diclofenac sodium, 22) duloxetine hydrochloride, 23) atorvastatin calcium, 24) leflunomide, 25) fluconazole. A participant could have received \>=1 most common medication.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 20 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 54 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 163 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 38 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 155 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 161 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 47 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 47 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 58 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 35 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 56 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 69 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 43 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 70 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 58 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 349 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 74 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 75 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 27 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 66 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 30 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 56 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 49 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 12 Participants |
| Tofacitinib XR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 47 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 41 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 56 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 51 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 136 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 41 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 116 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 50 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 34 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 49 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 38 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 41 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 11 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 59 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 87 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 16 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 185 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 64 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 85 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 54 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 48 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 35 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 75 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 26 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 304 Participants |
| Tofacitinib IR | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 49 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 642 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 387 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 397 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 433 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 2,717 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 300 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 311 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 320 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 318 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 427 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 332 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 1,789 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 339 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 1,473 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 1,616 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 322 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 327 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 180 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 621 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 463 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 508 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 497 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 665 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 503 Participants |
| Adalimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 391 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 36 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 7 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 38 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 42 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 33 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 11 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 109 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 106 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 19 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 20 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 49 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 13 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 28 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 23 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 36 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 21 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 25 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 23 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 120 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 23 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 25 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 31 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 33 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 34 Participants |
| Certolizumab Pegol | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 36 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 195 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 259 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 289 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 123 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 341 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 357 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 501 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 253 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 447 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 293 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 321 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 369 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 1,078 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 479 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 312 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 215 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 1,943 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 314 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 238 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 288 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 1,193 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 388 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 269 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 353 Participants |
| Etanercept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 1,053 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 45 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 221 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 201 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 6 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 111 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 72 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 41 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 245 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 12 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 76 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 64 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 67 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 61 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 66 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 50 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 68 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 55 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 62 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 3 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 62 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 47 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 44 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 52 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 44 Participants |
| Infliximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 42 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 43 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 89 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 58 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 61 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 55 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 92 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 67 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 12 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 75 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 83 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 11 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 53 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 252 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 9 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 40 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 64 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 96 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 56 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 53 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 234 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 49 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 62 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 54 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 58 Participants |
| Golimumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 214 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 49 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 33 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 56 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 53 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 55 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 34 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 61 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 80 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 37 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 78 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 58 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 28 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 50 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 2 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 62 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 82 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 1 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 7 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 39 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 148 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 191 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 45 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 38 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 36 Participants |
| Rituximab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 163 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 18 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 43 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 35 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 44 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 36 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 44 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 29 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 39 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 129 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 9 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 10 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 26 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 34 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 105 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 27 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 32 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 32 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 31 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 66 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 38 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 8 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 95 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 30 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 40 Participants |
| Tocilizumab | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 19 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluconazole | 68 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Albuterol Sulfate | 99 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Cyclobenzaprine Hydrochloride | 67 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Fluticasone Propionate | 83 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Folic Acid | 268 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Adalimumab | 19 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Atorvastatin Calcium | 74 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Etanercept | 25 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tramadol Hydrochloride | 107 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Tofacitinib Citrate | 33 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Hydroxychloroquine Sulfate | 163 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Leflunomide | 70 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methotrexate Sodium | 289 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Meloxicam | 68 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin/Clavulanate Potassium | 90 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Prednisone | 306 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Methylprednisolone | 104 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Acetaminophen/Hydrocodone Bitartrate | 159 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Omeprazole | 89 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Levothyroxine Sodium | 124 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Gabapentin | 113 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Azithromycin | 151 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Duloxetine Hydrochloride | 75 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Amoxicillin | 93 Participants |
| Abatacept | Number of Participants for Each of the Most Commonly Used Medications During the 12 Months Post-index Date | Diclofenac Sodium | 72 Participants |
Primary
Number of Participants Who Discontinued Then Restarted Index Medication
Participants were classified as discontinued and then restarted index medication if there was a gap in the index therapy of at least 60 days and the first medication observed after the gap was the index medication.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Discontinued Then Restarted Index Medication | 43 Participants |
| Tofacitinib IR | Number of Participants Who Discontinued Then Restarted Index Medication | 33 Participants |
| Adalimumab | Number of Participants Who Discontinued Then Restarted Index Medication | 201 Participants |
| Certolizumab Pegol | Number of Participants Who Discontinued Then Restarted Index Medication | 15 Participants |
| Etanercept | Number of Participants Who Discontinued Then Restarted Index Medication | 152 Participants |
| Infliximab | Number of Participants Who Discontinued Then Restarted Index Medication | 21 Participants |
| Golimumab | Number of Participants Who Discontinued Then Restarted Index Medication | 55 Participants |
| Rituximab | Number of Participants Who Discontinued Then Restarted Index Medication | 197 Participants |
| Tocilizumab | Number of Participants Who Discontinued Then Restarted Index Medication | 21 Participants |
| Abatacept | Number of Participants Who Discontinued Then Restarted Index Medication | 52 Participants |
Primary
Number of Participants Who Discontinued Then Switched From Index Medication
Participants were classified as discontinued and then switched from index medication if there was a gap in the index therapy of at least 60 days and the first medication observed after the gap was a bDMARD (including tofacitinib) different from index medication.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Discontinued Then Switched From Index Medication | 12 Participants |
| Tofacitinib IR | Number of Participants Who Discontinued Then Switched From Index Medication | 24 Participants |
| Adalimumab | Number of Participants Who Discontinued Then Switched From Index Medication | 127 Participants |
| Certolizumab Pegol | Number of Participants Who Discontinued Then Switched From Index Medication | 15 Participants |
| Etanercept | Number of Participants Who Discontinued Then Switched From Index Medication | 130 Participants |
| Infliximab | Number of Participants Who Discontinued Then Switched From Index Medication | 7 Participants |
| Golimumab | Number of Participants Who Discontinued Then Switched From Index Medication | 24 Participants |
| Rituximab | Number of Participants Who Discontinued Then Switched From Index Medication | 19 Participants |
| Tocilizumab | Number of Participants Who Discontinued Then Switched From Index Medication | 11 Participants |
| Abatacept | Number of Participants Who Discontinued Then Switched From Index Medication | 25 Participants |
Primary
Number of Participants Who Discontinued Without Switching or Restarting Index Medication
Participants were classified as discontinued without switching or restarting index medication if they had a gap in therapy of at least 60 days and there were no claims for either the index medication or a different bDMARD for the remainder of the follow-up period.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 70 Participants |
| Tofacitinib IR | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 62 Participants |
| Adalimumab | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 478 Participants |
| Certolizumab Pegol | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 54 Participants |
| Etanercept | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 303 Participants |
| Infliximab | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 62 Participants |
| Golimumab | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 54 Participants |
| Rituximab | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 101 Participants |
| Tocilizumab | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 51 Participants |
| Abatacept | Number of Participants Who Discontinued Without Switching or Restarting Index Medication | 98 Participants |
Primary
Number of Participants Who Met Different Medication Effectiveness Criteria
Adherence criteria: PDC \>=0.8, proportion of days of supply during post-index period of 12 months.Dose escalation criteria: no increase in dose for index drug compared to starting dose during post-index period. Switch criteria: no switching from index drug to (different) biologic agent during post-index period. DMARD criteria: no addition of new csDMARD to index drug during post-index period. Oral glucocorticoid criteria: Participants with no claims for oral glucocorticoids in 6 months pre-index cannot receive oral glucocorticoids for greater than (\>)30 days between (index date +91 days) to (index date + 365 days); or participants with claims for oral glucocorticoids in 6 months pre-index no increase in oral glucocorticoid dose during months 6-12 post-index.Injectable glucocorticoid criteria: at most 1 parenteral or intra-articular glucocorticoid joint injection on unique days after participant had been on bDMARD treatment for \>3 months between (index date + 91) to (index date + 365).
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 168 Participants |
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 294 Participants |
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 306 Participants |
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 285 Participants |
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 333 Participants |
| Tofacitinib XR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 316 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 288 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 240 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 208 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 98 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 270 Participants |
| Tofacitinib IR | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 242 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 1249 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 2263 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 2362 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 2308 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 2458 Participants |
| Adalimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 2001 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 165 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 144 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 149 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 64 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 190 Participants |
| Certolizumab Pegol | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 160 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 1864 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 843 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 1349 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 1727 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 1652 Participants |
| Etanercept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 1605 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 293 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 199 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 246 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 222 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 288 Participants |
| Infliximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 314 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 292 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 339 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 373 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 316 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 30 Participants |
| Golimumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 291 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 298 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 140 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 299 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 269 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 206 Participants |
| Rituximab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 0 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 72 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 159 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 151 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 202 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 185 Participants |
| Tocilizumab | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 167 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met DMARD criteria | 462 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid oral criteria | 429 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met switch criteria | 393 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met glucocorticoid injection criteria | 406 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met adherence criteria | 223 Participants |
| Abatacept | Number of Participants Who Met Different Medication Effectiveness Criteria | Met dose escalation criteria | 522 Participants |
Primary
Number of Participants Who Re-started Index Medication at Any Time
Participants who had a claim for the index medication any time after they were considered non-persistent with the index treatment (i.e, including after switching) during the 12-month follow-up are reported. Non-persistence was defined as the gap of at least 60 days in treatment with the index medication or switching to other biologic.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Re-started Index Medication at Any Time | 25 Participants |
| Tofacitinib IR | Number of Participants Who Re-started Index Medication at Any Time | 25 Participants |
| Adalimumab | Number of Participants Who Re-started Index Medication at Any Time | 132 Participants |
| Certolizumab Pegol | Number of Participants Who Re-started Index Medication at Any Time | 6 Participants |
| Etanercept | Number of Participants Who Re-started Index Medication at Any Time | 78 Participants |
| Infliximab | Number of Participants Who Re-started Index Medication at Any Time | 13 Participants |
| Golimumab | Number of Participants Who Re-started Index Medication at Any Time | 25 Participants |
| Rituximab | Number of Participants Who Re-started Index Medication at Any Time | 188 Participants |
| Tocilizumab | Number of Participants Who Re-started Index Medication at Any Time | 9 Participants |
| Abatacept | Number of Participants Who Re-started Index Medication at Any Time | 31 Participants |
Primary
Number of Participants Who Switched Any Time From Index Medication
Number of participants who switched from index medication to a biologic at any time during post-index period are reported.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Switched Any Time From Index Medication | 55 Participants |
| Tofacitinib IR | Number of Participants Who Switched Any Time From Index Medication | 96 Participants |
| Adalimumab | Number of Participants Who Switched Any Time From Index Medication | 727 Participants |
| Certolizumab Pegol | Number of Participants Who Switched Any Time From Index Medication | 48 Participants |
| Etanercept | Number of Participants Who Switched Any Time From Index Medication | 599 Participants |
| Infliximab | Number of Participants Who Switched Any Time From Index Medication | 56 Participants |
| Golimumab | Number of Participants Who Switched Any Time From Index Medication | 84 Participants |
| Rituximab | Number of Participants Who Switched Any Time From Index Medication | 26 Participants |
| Tocilizumab | Number of Participants Who Switched Any Time From Index Medication | 45 Participants |
| Abatacept | Number of Participants Who Switched Any Time From Index Medication | 140 Participants |
Primary
Number of Participants Who Switched Immediately From Index Medication
Participants were classified as switched immediately if they initiated a non-index bDMARD before a 60-day gap in index medication treatment.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Switched Immediately From Index Medication | 41 Participants |
| Tofacitinib IR | Number of Participants Who Switched Immediately From Index Medication | 70 Participants |
| Adalimumab | Number of Participants Who Switched Immediately From Index Medication | 575 Participants |
| Certolizumab Pegol | Number of Participants Who Switched Immediately From Index Medication | 33 Participants |
| Etanercept | Number of Participants Who Switched Immediately From Index Medication | 451 Participants |
| Infliximab | Number of Participants Who Switched Immediately From Index Medication | 49 Participants |
| Golimumab | Number of Participants Who Switched Immediately From Index Medication | 55 Participants |
| Rituximab | Number of Participants Who Switched Immediately From Index Medication | 3 Participants |
| Tocilizumab | Number of Participants Who Switched Immediately From Index Medication | 34 Participants |
| Abatacept | Number of Participants Who Switched Immediately From Index Medication | 112 Participants |
Primary
Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period
Number of participants who used at least 1 opioid and NSAID during post-index period are reported.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 210 Participants |
| Tofacitinib IR | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 205 Participants |
| Adalimumab | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 1,623 Participants |
| Certolizumab Pegol | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 104 Participants |
| Etanercept | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 1,236 Participants |
| Infliximab | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 233 Participants |
| Golimumab | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 249 Participants |
| Rituximab | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 202 Participants |
| Tocilizumab | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 143 Participants |
| Abatacept | Number of Participants Who Used Opioids and Non-steroidal Anti-inflammatory Drug (NSAIDs) During 12 Months Post Index Period | 342 Participants |
Primary
Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period
Number of participants who used opioids and NSAIDs during tofacitinib persistency and post-persistency are reported. Persistence with the index medication was defined as not having a gap in therapy of at least 60 days between fills/infusions.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tofacitinib XR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 138 Participants |
| Tofacitinib XR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 22 Participants |
| Tofacitinib XR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 94 Participants |
| Tofacitinib XR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 20 Participants |
| Tofacitinib IR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 31 Participants |
| Tofacitinib IR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 128 Participants |
| Tofacitinib IR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 26 Participants |
| Tofacitinib IR | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 85 Participants |
| Adalimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 182 Participants |
| Adalimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 1,035 Participants |
| Adalimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 769 Participants |
| Adalimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 157 Participants |
| Certolizumab Pegol | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 61 Participants |
| Certolizumab Pegol | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 20 Participants |
| Certolizumab Pegol | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 43 Participants |
| Certolizumab Pegol | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 16 Participants |
| Etanercept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 535 Participants |
| Etanercept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 167 Participants |
| Etanercept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 144 Participants |
| Etanercept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 774 Participants |
| Infliximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 100 Participants |
| Infliximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 23 Participants |
| Infliximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 168 Participants |
| Infliximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 17 Participants |
| Golimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 18 Participants |
| Golimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 122 Participants |
| Golimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 26 Participants |
| Golimumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 177 Participants |
| Rituximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 78 Participants |
| Rituximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 62 Participants |
| Rituximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 85 Participants |
| Rituximab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 39 Participants |
| Tocilizumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 8 Participants |
| Tocilizumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 104 Participants |
| Tocilizumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 60 Participants |
| Tocilizumab | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 17 Participants |
| Abatacept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs While Persistent | 146 Participants |
| Abatacept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids While Persistent | 246 Participants |
| Abatacept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used NSAIDs After Persistent | 25 Participants |
| Abatacept | Number of Participants Who Used Opioids and NSAIDs While Persistent and After Persistent With Index Medication During 12 Months Post Index Period | Used Opioids After Persistent | 41 Participants |
Primary
Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period
The number of participants who used at least 1 oral corticosteroid during the 12 months post-index period are reported.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 198 Participants |
| Tofacitinib IR | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 216 Participants |
| Adalimumab | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 1,713 Participants |
| Certolizumab Pegol | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 126 Participants |
| Etanercept | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 1,225 Participants |
| Infliximab | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 241 Participants |
| Golimumab | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 241 Participants |
| Rituximab | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 217 Participants |
| Tocilizumab | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 138 Participants |
| Abatacept | Number of Participants Who Used Oral Corticosteroids During 12 Months Post-Index Period | 356 Participants |
Primary
Number of Participants Who Were Non-persistent to Index Medication
Non-persistence was defined as the gap of at least 60 days in treatment with the index medication or switching to other biologic.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tofacitinib XR | Number of Participants Who Were Non-persistent to Index Medication | 166 Participants |
| Tofacitinib IR | Number of Participants Who Were Non-persistent to Index Medication | 189 Participants |
| Adalimumab | Number of Participants Who Were Non-persistent to Index Medication | 1381 Participants |
| Certolizumab Pegol | Number of Participants Who Were Non-persistent to Index Medication | 117 Participants |
| Etanercept | Number of Participants Who Were Non-persistent to Index Medication | 1036 Participants |
| Infliximab | Number of Participants Who Were Non-persistent to Index Medication | 139 Participants |
| Golimumab | Number of Participants Who Were Non-persistent to Index Medication | 188 Participants |
| Rituximab | Number of Participants Who Were Non-persistent to Index Medication | 320 Participants |
| Tocilizumab | Number of Participants Who Were Non-persistent to Index Medication | 117 Participants |
| Abatacept | Number of Participants Who Were Non-persistent to Index Medication | 287 Participants |
Primary
Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date
In this outcome measure number of participants who were on combination therapy with index medication and who were on monotherapy during 12 months pre-index date were reported. Participants with a use of at least 1 of 4 specific csDMARDs (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide) within 90 days on or after the index date were considered as being treated with combination therapy. Participants who did not take any csDMARDs along with index medication were considered being treated with monotherapy.
Time frame: Within 90 days after index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tofacitinib XR | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 183 Participants |
| Tofacitinib XR | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 166 Participants |
| Tofacitinib IR | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 168 Participants |
| Tofacitinib IR | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 136 Participants |
| Adalimumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 2001 Participants |
| Adalimumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 727 Participants |
| Certolizumab Pegol | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 119 Participants |
| Certolizumab Pegol | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 73 Participants |
| Etanercept | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 1373 Participants |
| Etanercept | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 575 Participants |
| Infliximab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 266 Participants |
| Infliximab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 83 Participants |
| Golimumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 279 Participants |
| Golimumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 97 Participants |
| Rituximab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 131 Participants |
| Rituximab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 194 Participants |
| Tocilizumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 103 Participants |
| Tocilizumab | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 101 Participants |
| Abatacept | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Monotherapy | 183 Participants |
| Abatacept | Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date | Combination therapy | 350 Participants |
Primary
Proportion of Days Covered (PDC)
The PDC was calculated based on total days supply over the 12 months follow-up. The PDC was calculated by using the date of service and the day supply for each fill of the index medication.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tofacitinib XR | Proportion of Days Covered (PDC) | 0.65 proportion of days | Standard Deviation 0.32 |
| Tofacitinib IR | Proportion of Days Covered (PDC) | 0.55 proportion of days | Standard Deviation 0.32 |
| Adalimumab | Proportion of Days Covered (PDC) | 0.66 proportion of days | Standard Deviation 0.31 |
| Certolizumab Pegol | Proportion of Days Covered (PDC) | 0.56 proportion of days | Standard Deviation 0.32 |
| Etanercept | Proportion of Days Covered (PDC) | 0.63 proportion of days | Standard Deviation 0.32 |
| Infliximab | Proportion of Days Covered (PDC) | 0.77 proportion of days | Standard Deviation 0.28 |
| Golimumab | Proportion of Days Covered (PDC) | 0.46 proportion of days | Standard Deviation 0.2 |
| Rituximab | Proportion of Days Covered (PDC) | 0.63 proportion of days | Standard Deviation 0.48 |
| Tocilizumab | Proportion of Days Covered (PDC) | 0.60 proportion of days | Standard Deviation 0.31 |
| Abatacept | Proportion of Days Covered (PDC) | 0.63 proportion of days | Standard Deviation 0.31 |
Primary
RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period
RA related total health care costs, medical costs, pharmacy costs during 12 months post-index period are reported. RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs).
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Tofacitinib XR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 44,134.19 dollars |
| Tofacitinib XR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 38,526.59 dollars |
| Tofacitinib XR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 5,058.93 dollars |
| Tofacitinib IR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 4,603.61 dollars |
| Tofacitinib IR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 38,462.40 dollars |
| Tofacitinib IR | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 32,697.22 dollars |
| Adalimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 4,650.27 dollars |
| Adalimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 54,892.62 dollars |
| Adalimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 48,872.33 dollars |
| Certolizumab Pegol | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 17,384.65 dollars |
| Certolizumab Pegol | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 5,685.44 dollars |
| Certolizumab Pegol | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 41,845.23 dollars |
| Etanercept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 4,532.83 dollars |
| Etanercept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 50,531.75 dollars |
| Etanercept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 45,093.62 dollars |
| Infliximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 9,543.27 dollars |
| Infliximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 42,227.78 dollars |
| Infliximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 3,679.43 dollars |
| Golimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 43,897.47 dollars |
| Golimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 9,565.34 dollars |
| Golimumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 5,799.47 dollars |
| Rituximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 15,333.99 dollars |
| Rituximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 55,383.00 dollars |
| Rituximab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 3,667.78 dollars |
| Tocilizumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 6,666.27 dollars |
| Tocilizumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 37,868.85 dollars |
| Tocilizumab | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 18,471.52 dollars |
| Abatacept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Total health care costs | 49,156.67 dollars |
| Abatacept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Pharmacy costs | 20,603.02 dollars |
| Abatacept | RA Related Total Health Care Costs, Medical Costs, Pharmacy Costs During 12 Months Post-Index Period | Medical costs | 7,330.20 dollars |
Primary
Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period
RA related inpatient visit costs consisted of expenses during hospital visits for formal admission for RA. Outpatient visit costs consisted of expenses when participants visited hospital but not for formal admission for RA. ER visit costs consisted of expenses during visit to ER of hospital for RA.
Time frame: During 12 months post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Tofacitinib XR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 2,257.47 dollars |
| Tofacitinib XR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,465.50 dollars |
| Tofacitinib XR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 335.97 dollars |
| Tofacitinib IR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 359.62 dollars |
| Tofacitinib IR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,470.87 dollars |
| Tofacitinib IR | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 1,773.11 dollars |
| Adalimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 374.24 dollars |
| Adalimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,215.74 dollars |
| Adalimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 2,060.29 dollars |
| Certolizumab Pegol | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 1,794.11 dollars |
| Certolizumab Pegol | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 351.14 dollars |
| Certolizumab Pegol | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 3,540.19 dollars |
| Etanercept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 356.14 dollars |
| Etanercept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,054.38 dollars |
| Etanercept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 2,122.31 dollars |
| Infliximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 569.19 dollars |
| Infliximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 5,412.86 dollars |
| Infliximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 3,561.22 dollars |
| Golimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,034.70 dollars |
| Golimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 3,348.09 dollars |
| Golimumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 416.68 dollars |
| Rituximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 9,991.58 dollars |
| Rituximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 403.89 dollars |
| Rituximab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 4,938.52 dollars |
| Tocilizumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 345.85 dollars |
| Tocilizumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,143.98 dollars |
| Tocilizumab | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 4,176.44 dollars |
| Abatacept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Outpatient visits costs | 4,166.63 dollars |
| Abatacept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | Inpatient visits costs | 2,678.39 dollars |
| Abatacept | Rheumatoid Arthritis (RA) Related Inpatient Visits Costs, Outpatient Visits Costs and Emergency Room (ER) Visits Costs During 12 Months Post Index Period | ER visits costs | 485.19 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 10 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 10 post-index date.
Time frame: Month 10 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 5,670.69 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 3,939.86 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 5,186.08 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 3,998.95 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 4,698.56 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 4,147.01 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 3,975.54 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 6,545.01 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 3,938.69 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 10 Post Index Date | 5,073.34 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 11 Post-index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 11 post-index date.
Time frame: Month 11 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 4,244.03 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 4,083.34 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 5,032.88 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 4,500.99 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 5,202.71 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 4,334.84 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 4,861.39 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 6,109.10 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 5,248.98 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 11 Post-index Date | 5,180.75 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 12 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 12 post-index date.
Time frame: Month 12 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 6,497.03 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 4,229.36 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 5,009.64 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 4,128.34 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 4,918.79 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 4,085.60 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 3,203.10 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 7,144.07 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 5,668.30 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 12 Post Index Date | 5,571.79 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 1 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 1 post-index date.
Time frame: Month 1 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 7,985.18 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 6,989.92 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 9,290.98 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 10,394.75 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 8,777.27 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 8,794.60 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 11,036.55 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 27,231.41 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 7,265.53 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 1 Post Index Date | 10,278.66 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 2 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 2 post-index date.
Time frame: Month 2 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,805.26 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 3,207.83 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,661.95 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,734.42 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,735.15 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,915.29 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 3,205.10 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 5,169.15 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,244.12 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 2 Post Index Date | 4,716.32 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 3 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 3 post-index date.
Time frame: Month 3 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,093.95 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 4,551.06 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,975.14 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 6,950.34 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,674.03 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 3,047.15 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,139.77 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,857.31 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 5,861.37 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 3 Post Index Date | 6,395.67 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 4 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 4 of post-index date.
Time frame: Month 4 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,079.28 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 3,969.48 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,301.22 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,014.75 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,120.19 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,346.93 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 4,221.26 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,344.44 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,977.41 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 4 Post Index Date | 5,412.70 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 5 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 5 post-index date.
Time frame: Month 5 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,122.15 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,874.41 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,828.27 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,102.21 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,915.71 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 3,363.56 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 5,709.69 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,837.39 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,489.84 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 5 Post Index Date | 4,951.42 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 6 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 6 post-index date.
Time frame: Month 6 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 4,867.20 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 3,826.79 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 5,997.83 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 4,830.11 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 4,982.15 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 4,626.76 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 3,115.80 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 5,442.79 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 4,359.39 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 6 Post Index Date | 5,059.37 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 7 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 7 post-index date.
Time frame: Month 7 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,950.36 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,939.24 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 5,004.78 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,392.10 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,817.34 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 3,067.81 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,677.76 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 8,433.49 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 4,465.05 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 7 Post Index Date | 5,874.66 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 8 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 8 post-index date.
Time frame: Month 8 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 3,815.56 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 4,139.87 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 5,021.37 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 5,095.74 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 5,068.81 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 4,943.14 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 3,709.37 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 8,202.13 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 4,886.07 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 8 Post Index Date | 5,745.10 dollars |
Primary
Total All Cause Monthly Health Care Cost at Month 9 Post Index Date
All cause refers to cost spent due to all comorbidities including RA. Total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure total all cause health care cost in dollars is reported for Month 9 post-index date.
Time frame: Month 9 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 4,300.84 dollars |
| Tofacitinib IR | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 4,399.74 dollars |
| Adalimumab | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,335.04 dollars |
| Certolizumab Pegol | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 3,921.54 dollars |
| Etanercept | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,210.21 dollars |
| Infliximab | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,064.33 dollars |
| Golimumab | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,292.97 dollars |
| Rituximab | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,049.22 dollars |
| Tocilizumab | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,716.07 dollars |
| Abatacept | Total All Cause Monthly Health Care Cost at Month 9 Post Index Date | 5,249.20 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 10 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 10 post-index date.
Time frame: Month 10 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 3,416.78 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,848.24 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 4,146.86 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,519.73 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 3,677.71 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,989.40 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,972.93 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,816.24 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 2,515.85 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 10 Post Index Date | 3,591.22 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 11 Post-index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 11 post-index date.
Time frame: Month 11 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,010.75 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 2,418.53 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,926.41 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 2,861.97 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,793.28 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 2,982.23 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,473.65 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,261.20 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,239.53 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 11 Post-index Date | 3,588.33 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 12 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 12 post-index date.
Time frame: Month 12 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 3,971.99 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,929.00 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 4,018.90 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,772.76 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 3,645.36 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,812.13 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,169.49 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,441.00 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 2,389.17 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 12 Post Index Date | 3,655.69 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 1 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 1 post-index date.
Time frame: Month 1 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 6,743.68 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 6,021.42 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 8,562.89 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 9,390.90 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 7,943.89 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 7,850.66 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 10,152.78 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 22,346.69 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 5,595.28 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 1 Post Index Date | 8,937.97 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 2 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measurec RA related total all cause health care cost in dollars is reported for Month 2 post-index date.
Time frame: Month 2 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,998.35 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,450.14 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 3,876.12 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,761.42 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 3,639.87 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 3,941.04 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,102.21 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,376.90 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 2,478.72 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 2 Post Index Date | 3,378.57 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 3 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 3 post-index date.
Time frame: Month 3 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 3,747.82 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 3,494.46 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 5,049.33 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 3,829.80 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 4,522.20 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 2,108.64 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 4,157.90 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 2,487.38 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 3,696.15 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 3 Post Index Date | 3,987.88 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 4 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 4 post-index date.
Time frame: Month 4 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 3,935.88 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 2,932.92 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 4,279.35 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 3,333.94 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 4,058.48 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 4,336.50 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 2,982.49 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 1,660.75 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 3,209.19 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 4 Post Index Date | 3,871.96 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 5 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 5 post-index date.
Time frame: Month 5 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 2,872.41 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 3,192.69 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 3,951.04 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 2,631.47 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 3,715.18 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 2,408.72 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 4,017.58 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 2,442.36 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 2,886.74 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 5 Post Index Date | 3,430.00 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 6 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 6 post-index date.
Time frame: Month 6 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 3,914.17 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 2,567.31 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 4,657.35 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 3,208.61 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 4,017.72 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 3,257.63 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 2,207.60 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 2,225.86 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 2,848.72 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 6 Post Index Date | 3,614.41 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 7 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 7 post-index date.
Time frame: Month 7 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,493.19 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,724.00 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,937.19 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,091.38 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,745.42 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 2,156.48 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,623.70 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 5,701.51 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 2,873.86 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 7 Post Index Date | 3,980.53 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 8 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 8 post-index date.
Time frame: Month 8 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 2,724.51 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 2,945.03 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 4,118.25 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 2,660.95 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 3,837.85 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 3,849.37 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 2,597.10 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 5,004.67 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 3,122.90 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 8 Post Index Date | 3,781.65 dollars |
Primary
Total RA Related Monthly Health Care Cost at Month 9 Post Index Date
RA related total health care cost was calculated as the total of pharmacy cost (home healthcare cost, urgent care cost and other medical services costs) and medical cost (ambulatory cost, emergency department visits cost, inpatient admission cost and other costs). In this outcome measure RA related total all cause health care cost in dollars is reported for Month 9 post-index date.
Time frame: Month 9 post-index date (index date =date of first claim for index medication [bDMARDs or tofacitinib] during identification period of 3.5 years)
Population: Analysis was performed on all participants included in the study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Tofacitinib XR | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,304.66 dollars |
| Tofacitinib IR | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 2,938.67 dollars |
| Adalimumab | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 4,368.93 dollars |
| Certolizumab Pegol | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 2,782.29 dollars |
| Etanercept | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,934.80 dollars |
| Infliximab | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,535.00 dollars |
| Golimumab | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,440.04 dollars |
| Rituximab | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 2,618.44 dollars |
| Tocilizumab | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,012.74 dollars |
| Abatacept | Total RA Related Monthly Health Care Cost at Month 9 Post Index Date | 3,338.46 dollars |